The US Meals and Drug Administration (FDA) has granted Breakthrough Remedy Designation (BTD) to VER-01, the flagship full-spectrum hashish drug from Munich-based Vertanical, placing it in prime place to develop into the primary FDA-approved cannabis-derived drugs for ache, and solely the second such approval since Epidiolex in 2018.
VER-01’s FDA designation, granted on 18 Could 2026, is reserved for investigational medicines exhibiting the potential for substantial enchancment over present therapies in critical situations.
Whereas this doesn’t imply Vertanical has now achieved FDA approval for its non-opioid therapy for persistent low again ache, it marks a major milestone as the corporate prepares for advertising and marketing authorisation in its first European markets inside weeks.
The timing comes simply weeks after the US formally moved medical hashish to Schedule III, recognising hashish therapy’s medical advantages for the primary time in its historical past.
As Enterprise of Hashish reported in December, VER-01’s designation follows two Section 3 randomised managed trials (RCTs).
READ MORE…
In a placebo-controlled examine of 820 sufferers printed in Nature Medication in September 2025, VER-01 met its main endpoint with results sustained over the long run and important enhancements in sleep and bodily operate.
A second head-to-head comparator examine, the ELEVATE trial, throughout 384 sufferers in Germany, the Czech Republic, Poland and Spain, discovered VER-01 delivered superior ache discount and higher gastrointestinal tolerability in contrast with opioids, with no proof of dependence or withdrawal.
“We consider VER-01 has the potential to vary how persistent ache is handled and provide physicians a much-needed non-opioid resolution,” stated Dr Clemens Fischer, Chief Government Officer of FUTRUE Group and Founding father of Vertanical.
Throughout the Atlantic, Vertanical can be on the verge of launching its breakthrough therapy in European markets, which the corporate says is predicted inside weeks.
As soon as Germany grants approval as an authorised medicinal product, the EU mutual recognition process offers the path to broader continental entry. VER-01 can be marketed beneath the identify Exilby, and has been seven years in growth at a value exceeding $250m
With Epidiolex, Jazz Prescription drugs’ market-leading CBD therapy for uncommon epilepsies, producing roughly $100m in annual gross sales, Vertanical is concentrating on a considerably bigger market with a persistent low again ache therapy, which impacts an estimated half a billion individuals worldwide.
Within the US, Vertanical has initiated an extra pivotal Section 3 trial to fulfill FDA necessities, with a primary knowledge read-out anticipated in 2027 and an NDA deliberate for 2028, topic to optimistic outcomes.
Greater than 60 million Individuals endure from persistent ache, one in 5 sufferers with acute ache are nonetheless prescribed opioids for need of options.
The BTD additionally carries a particular implication that has obtained little consideration within the wider rescheduling protection. At Hashish Europa London this week, audio system with direct regulatory expertise drew a distinction that issues for any European firm watching the US market develop.
Talking on the occasion, Saphira Galoob, Government Director of the US Hashish Roundtable, defined that the April order covers two classes, FDA-approved medication containing hashish and merchandise regulated beneath state-licensed markets.
“There’s actually just one true cannabis-derived drug product that FDA has ever accepted, which is Epidiolex,” stated Jonathan Havens, who co-founded the hashish regulation follow at Saul Ewing and served as regulatory counsel on the FDA earlier than getting into personal follow.
Artificial analogues similar to Marinol and Syndros are additionally already Schedule III, he famous, however are usually not derived from the hashish plant.
VER-01’s NDA pathway, accelerated by the BTD, is a path to becoming a member of Epidiolex in that first class. FDA-approved Schedule III medicines qualify for normal hospital formularies, insurance coverage reimbursement negotiations, and prescribing by any licensed doctor, with out the compliance structure that state-licensed operators should navigate.
There’s a additional business dimension that rescheduling has opened, although it stays incomplete in follow. Galoob famous that beneath US regulation, medical hashish merchandise can now be exported.
Havens additionally famous that the DEA’s closing order contemplates import and export for registered producers, importers and exporters, however the registration portal has solely simply opened, and the primary wave coated dispensaries solely.
“The ultimate order says that it’s contemplated, that’s allowed technically at this time,” Havens advised delegates throughout a packed panel dialogue.
“I don’t assume there’s a straightforward technique to do it till we begin to hear from the DEA on who they’re deciding to register.”
Nevertheless, Vertanical’s BTD designation presents its path to market extra safety from the ever-shifting politics of hashish rescheduling.
VER-01 is a standardised full-spectrum extract from the proprietary Hashish sativa pressure DKJ127 L., containing an outlined combination of cannabinoids, terpenes and bioactive compounds, together with cannabigerol, β-caryophyllene and α-bisabolol. It’s administered orally as liquid drops. Vertanical is express that its findings can’t be extrapolated to different hashish extracts or prescribed flower merchandise.
European advertising and marketing authorisation would be the subsequent important milestone to observe. Ought to Germany proceed as anticipated within the coming weeks, the mutual recognition file will decide how shortly the remainder of the EU follows.
